I'm proud to ride a third year in support of the PMC as Living Proof of cancer survivorship.
In the last year I received 7 months of very slow infusion of chemotherapy because I developed an allergic reaction to two of the frontline chemos. One of the reactions was severe and had me out of action for a week. Since January 2025, I am receiving chemotherapy treatment three out of four weeks at Dana Farber in Chestnut Hill. Side effects are nausea, fatigue, mild but frequent nose bleeding. Oh and hair loss!
My history: I was diagnosed in January 2018 with Stage 2 Ovarian Cancer. I underwent surgery and chemotherapy transfusions for 5 months. Lost hair, weight, fluid and blood transfusions, brain fog, neurapathy, but then I had No Evidence of Disease (NED) for 18 months. However, as is typical of OC, I had a reoccurrence at the start of covid pandemic in Feb 2020. I underwent six more months of chemotherapy. I was placed on, Olaparib, taken orally, in October 2020. Although Olaparib sapped my energy, it was effective for me for 3.5 years. Unfortunately the disease returned in February 2024. I retired July 2023, due to the fatigue but also have more freedom and flexibility to spend time with family and friends. I take life one CT or PET scan to the next and have a deeper appreciation of family, friends and the time I have now while I'm feeling well.
I am excited to ride again with our cousin Nareg and friends on the very successful Team Ovarian Cancer. With your help, I am happy that I am able to give back to Dana Farber for all the support I have received from the medical team, infusion nurses, scheduling staff, medical technicians, my social worker, and volunteers. The on-going research at DFCI is ground breaking, new treatments in development all the time, and I am glad I have been able to benefit from it.
This is the fourth year Team Ovarian Cancer is riding under the leadership of Nancy Cantor. Our goal in 2025 is to raise $300K. We have raised almost $1 million since our inception.
Meet our fearless leader Nancy and our friend and teammate Mara. Sadly Mara succumbed to the disease in Dec 2024. Team Ovarian Cancer-Why we ride
100% of rider-raised revenue went directly to support the Jimmy Fund and Dana-Farber Cancer Institute's tireless commitment to finding a cure. Our teams funds will go directly to helping Dr. Matulonis in her research on Natural Killer Cells. The team was authorized to begin a clinical trial in the fall of 2024. Here are her words on what the funding supports:
Our GYN group is exploring the potential of a promising avenue of immunotherapy called cytokine induced memory-like (CIML) natural killer (NK) cell therapy for use against recurrent ovarian cancer. NK cells are often described as the “shock troops” of the immune system, the first wave of defenders against infection and disease. They are called natural killers because they do not require any special preparation or training to go on the attack. Like a well-organized strike force, they deploy quickly, do their job, and disperse. NK cells were thought to lack the type of cellular memory found in their longer-lived immune system counterparts, such as T NK cells do not readily proliferate and have a fleeting lifespan of only a few days, leaving them largely unable to eliminate infected or diseased cells. The type of NK cells used are CIML (cytokine-induced memory-like) NK cells, they are stimulated by specific proteins known as cytokines that facilitate communication between cells of the immune system, which enhances their ability to recognize and eliminate cancer. CIML NK cells also show increased proliferation and longevity compared to typical NK cells. A novel approach developed at Dana-Farber combines the CIML NK cells, which have been preactivated with cytokines, with an IL-15 super-agonist, a compound that enhances the durability and effectiveness of the already amplified immune response. This regimen has shown promise in phase I trials for blood cancers including acute myeloid leukemia, and in one trial led to complete remission in seven out of 13 patients with difficult-to- treat relapsed/refractory disease. Dana-Farber is the only institution in the world currently evaluating CIML NK cell therapy in solid tumors.
The Division of Gynecologic Oncology has launched launch a clinical trial testing CIML NK cell therapy in combination with an IL-15 super-agonist and an immune checkpoint inhibitor for recurrent high- grade ovarian cancer. Designed as a phase I study, it will be the first-in-human trial of this immunotherapy combination for this disease subtype. We are looking forward to testing these supercharged NK cells to treat recurrent ovarian cancer.
Thank you so much for your donation.
Sincerely,
Barbara
I'm proud to ride a third year in support of the PMC as Living Proof of cancer survivorship.
In the last year I received 7 months of very slow infusion of chemotherapy because I developed an allergic reaction to two of the frontline chemos. One of the reactions was severe and had me out of action for a week. Since January 2025, I am receiving chemotherapy treatment three out of four weeks at Dana Farber in Chestnut Hill. Side effects are nausea, fatigue, mild but frequent nose bleeding. Oh and hair loss!
My history: I was diagnosed in January 2018 with Stage 2 Ovarian Cancer. I underwent surgery and chemotherapy transfusions for 5 months. Lost hair, weight, fluid and blood transfusions, brain fog, neurapathy, but then I had No Evidence of Disease (NED) for 18 months. However, as is typical of OC, I had a reoccurrence at the start of covid pandemic in Feb 2020. I underwent six more months of chemotherapy. I was placed on, Olaparib, taken orally, in October 2020. Although Olaparib sapped my energy, it was effective for me for 3.5 years. Unfortunately the disease returned in February 2024. I retired July 2023, due to the fatigue but also have more freedom and flexibility to spend time with family and friends. I take life one CT or PET scan to the next and have a deeper appreciation of family, friends and the time I have now while I'm feeling well.
I am excited to ride again with our cousin Nareg and friends on the very successful Team Ovarian Cancer. With your help, I am happy that I am able to give back to Dana Farber for all the support I have received from the medical team, infusion nurses, scheduling staff, medical technicians, my social worker, and volunteers. The on-going research at DFCI is ground breaking, new treatments in development all the time, and I am glad I have been able to benefit from it.
This is the fourth year Team Ovarian Cancer is riding under the leadership of Nancy Cantor. Our goal in 2025 is to raise $300K. We have raised almost $1 million since our inception.
Meet our fearless leader Nancy and our friend and teammate Mara. Sadly Mara succumbed to the disease in Dec 2024. Team Ovarian Cancer-Why we ride
100% of rider-raised revenue went directly to support the Jimmy Fund and Dana-Farber Cancer Institute's tireless commitment to finding a cure. Our teams funds will go directly to helping Dr. Matulonis in her research on Natural Killer Cells. The team was authorized to begin a clinical trial in the fall of 2024. Here are her words on what the funding supports:
Our GYN group is exploring the potential of a promising avenue of immunotherapy called cytokine induced memory-like (CIML) natural killer (NK) cell therapy for use against recurrent ovarian cancer. NK cells are often described as the “shock troops” of the immune system, the first wave of defenders against infection and disease. They are called natural killers because they do not require any special preparation or training to go on the attack. Like a well-organized strike force, they deploy quickly, do their job, and disperse. NK cells were thought to lack the type of cellular memory found in their longer-lived immune system counterparts, such as T NK cells do not readily proliferate and have a fleeting lifespan of only a few days, leaving them largely unable to eliminate infected or diseased cells. The type of NK cells used are CIML (cytokine-induced memory-like) NK cells, they are stimulated by specific proteins known as cytokines that facilitate communication between cells of the immune system, which enhances their ability to recognize and eliminate cancer. CIML NK cells also show increased proliferation and longevity compared to typical NK cells. A novel approach developed at Dana-Farber combines the CIML NK cells, which have been preactivated with cytokines, with an IL-15 super-agonist, a compound that enhances the durability and effectiveness of the already amplified immune response. This regimen has shown promise in phase I trials for blood cancers including acute myeloid leukemia, and in one trial led to complete remission in seven out of 13 patients with difficult-to- treat relapsed/refractory disease. Dana-Farber is the only institution in the world currently evaluating CIML NK cell therapy in solid tumors.
The Division of Gynecologic Oncology has launched launch a clinical trial testing CIML NK cell therapy in combination with an IL-15 super-agonist and an immune checkpoint inhibitor for recurrent high- grade ovarian cancer. Designed as a phase I study, it will be the first-in-human trial of this immunotherapy combination for this disease subtype. We are looking forward to testing these supercharged NK cells to treat recurrent ovarian cancer.
Thank you so much for your donation.
Sincerely,
Barbara
|
Eric Gutt |
$500.00 |
| 2025 | $500.00 | Wellesley to Patriot Place (25 mile Sunday) and Volunteer |
| 2024 | $12,775.00 | Wellesley to Patriot Place (25 mile Sunday) and Volunteer |
| 2023 | $5,975.20 | Wellesley to Patriot Place (25 mile Sunday) |
